LDL-Cholesterol: From the Hypothesis to Causality

被引：6

作者：

Custodis, Florian ^{[1
]}

Laufs, Ulrich ^{[1
]}

机构：

[1] Univ Klinikum Saarlandes, Abt Innere Med Kardiol Angiol & Internist Intensi, Homburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2015年 / 140卷 / 10期

关键词：

LDL; Cholesterol; LDL-Hypothesis; IMPROVE-IT; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; IMPROVE-IT; TRIALS; RISK; HYPERCHOLESTEROLEMIA; METAANALYSIS; SIMVASTATIN; PREVENTION; REDUCTION;

D O I：

10.1055/s-0041-102254

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The term "LDL-Hypothesis is frequently used to describe the association between LDL cholesterol (LDL-C) and cardiovascular outcomes. In the light of recent results of randomized trials the question arises whether the term hypothesis is still adequate. Considering the causal importance of LDL for the pathogenesis of atherosclerosis, epidemiological evidence and the clear genetic association of LDL-C with cardiovascular risk as well as the large statin trials and the reduction of events by a non-statin intervention in the IMPROVE-IT study, the term hypothesis appears to be outdated and should be replaced by LDL-causality.

引用

页码：761 / U71

页数：5

共 50 条

[31] RELATIONSHIPS BETWEEN LYMPHOCYTE CHOLESTEROL HOMEOSTASIS AND LDL-CHOLESTEROL
HAMBITZER, R
MELZNER, I
HAFERKAMP, O
CLINICAL BIOCHEMISTRY, 1987, 20 (02) : 97 - 104
[32] miRNA regulation of LDL-cholesterol metabolism
Goedeke, Leigh
Wagschal, Alexandre
Fernandez-Hernando, Carlos
Naar, Anders M.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2016, 1861 (12): : 2047 - 2052
[33] VALUE OF LDL-CHOLESTEROL DETERMINATION IN HYPERLIPOPROTEINEMIA
ALCINDOR, LG
AALAM, H
PIOT, MC
PRESSE MEDICALE, 1983, 12 (37): : 2319 - 2321
[34] NEW DRUGS FOR LOWERING LDL-CHOLESTEROL
Badescu, Codruta
Rezus, Elena
Badescu, L.
Dima, Nicoleta
Rezus, C.
MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 485 - 490
[35] Serotonin transporter polymorphism and LDL-cholesterol
P Fischer
E Gruenblatt
P Pietschmann
K-H Tragl
Molecular Psychiatry, 2006, 11 : 707 - 709
[36] Baseline levels of LDL-cholesterol and lipoprotein(A) and the Ava II polymorphism of the LDL receptor gene influence the response of LDL-cholesterol to pravastatin treatment
Lahoz, M
Pena, R
Mostaza, JM
Laguna, F
Garcia-Iglesias, MF
Taboada, K
Pinto, X
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 21 - 21
[37] The next chapter of prevention: from LDL-cholesterol to lipoprotein(a) and triglycerides
Luscher, Thomas F.
EUROPEAN HEART JOURNAL, 2020, 41 (24) : 2227 - 2230
[38] Comparison between small dense LDL-cholesterol and LDL-cholesterol to predict coronary events in stable coronary heart disease
Yokota, Yuuya
Koba, Shinji
Tsunoda, Fumiyoshi
Ban, Yoshihisa
Sato, Takayuki
Shoji, Makoto
Suzuki, Leroshi
Katagiri, Takashi
NEW FRONTIERS IN LIFESTYLE-RELATED DISEASES, 2008, : 147 - 153
[39] EVALUATION OF A DIRECT LDL-CHOLESTEROL (LDL-C) ASSAY
CHESLER, R
COSTELLO, R
CSAKO, G
CLINICAL CHEMISTRY, 1995, 41 (06) : S141 - S141
[40] ATORVASTATIN INCREASES PLASMA VITAMIN E/LDL-CHOLESTEROL AND COQ10/LDL-CHOLESTEROL RATIOS IN HYPERCHOLESTEROLAEMIC PATIENTS
Cheng, W-L
Kuo, C-L
Liu, C-S
ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)

← 1 2 3 4 5 →